Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9538.3333
Address
16 Miles Street Mulgrave, Victoria (VIC) 3170
Description
Optiscan Imaging Ltd. is engaged in the development of endomicroscopic imaging technologies for medical, translational and pre-clinical applications. It has developed and patented miniaturised confocal microscopes. Its products include FIVE2 and Customisation options. The company was founded by Martin Harris and Peter Maxwell Delaney in 1994 and is headquartered in Mulgrave, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.08 - 0.26
Trade Value (12mth)
AU$11,175.00
1 week
-1.67%
1 month
5.36%
YTD
-7.81%
1 year
71.51%
All time high
0.65
EPS 3 yr Growth
105.60%
EBITDA Margin
-679.10%
Operating Cashflow
-$6m
Free Cash Flow Return
-67.20%
ROIC
-70.90%
Interest Coverage
-331.00
Quick Ratio
7.40
Shares on Issue (Fully Dilluted)
835m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
10 April 25 |
Optiscan Site Tour - Analyst Presentation
×
Optiscan Site Tour - Analyst Presentation |
09 April 25 |
Optiscan to Showcase Imaging Tech at Site Tour
×
Optiscan to Showcase Imaging Tech at Site Tour |
31 March 25 |
Optiscan Announces New CFO & Other Executive Appointments
×
Optiscan Announces New CFO & Other Executive Appointments |
28 March 25 |
Optiscan to present at TSN ASX Gems Conference
×
Optiscan to present at TSN ASX Gems Conference |
28 March 25 |
Optiscan TSN ASX Gems Conference Presentation
×
Optiscan TSN ASX Gems Conference Presentation |
21 March 25 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
18 March 25 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
13 March 25 |
Change in substantial holding
×
Change in substantial holding |
10 March 25 |
Notification of cessation of securities - OIL
×
Notification of cessation of securities - OIL |
10 March 25 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
27 February 25 |
Appendix 4D
×
Appendix 4D |
27 February 25 |
Half-year Report - 31 December 2024
×
Half-year Report - 31 December 2024 |
27 February 25 |
Half Year Results
×
Half Year Results |
19 February 25 |
Optiscan Reveals InForm Imaging Device for Pathology
×
Optiscan Reveals InForm Imaging Device for Pathology |
04 February 25 |
Change of Company Secretary
×
Change of Company Secretary |
03 February 25 |
Optiscan Initiates GI Study in Germany with First Prototype
×
Optiscan Initiates GI Study in Germany with First Prototype |
31 January 25 |
Optiscan receives $1.775m R&D Tax Refund
×
Optiscan receives $1.775m R&D Tax Refund |
31 January 25 |
OIL December 2024 Quarterly Report and Appendix 4C
×
OIL December 2024 Quarterly Report and Appendix 4C |
06 December 24 |
Change in substantial holding
×
Change in substantial holding |
21 November 24 |
OIL Managing Director's Presentation & Chair's Address
×
OIL Managing Director's Presentation & Chair's Address |
21 November 24 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
18 November 24 |
Optiscan Signs Research Agreement with Minnesota Vet College
×
Optiscan Signs Research Agreement with Minnesota Vet College |
04 November 24 |
Optiscan Signs Agreement with Monash to Progress GI Scope
×
Optiscan Signs Agreement with Monash to Progress GI Scope |
31 October 24 |
OIL September 2024 Quarterly Report and Appendix 4C
×
OIL September 2024 Quarterly Report and Appendix 4C |
28 October 24 |
Optiscan Participates in Major US Industry Events
×
Optiscan Participates in Major US Industry Events |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.